Guided Therapeutics director converts $116K note

The converted amount included $50,000 of installments scheduled for October 2026 through February 2027, alongside $60,000 deferred from April through September 2026.

Rhea-AI Filing Summary

Guided Therapeutics Inc. director and 10% owner John E. Imhoff converted an outstanding $115,515.07 convertible note into 1,650,215 common shares on September 30, 2026, at $0.07 per share. The converted balance comprised $110,000 of principal and $5,515.07 of accrued interest. After conversion, his direct common-stock holdings were 22,902,888 shares, and the note was paid in full. No Rule 10b5-1 plan is reported.

Insider Trade Summary

1,650,215 shares exercised/converted

Exercise 2 txns

Insider Imhoff John E

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Conversion	Convertible Promissory Note F1	1,650,215	--	--
Conversion	Common Stock F1	1,650,215	$0.07	$116K

Holdings After Transaction: Convertible Promissory Note — 0 contracts (Direct); Common Stock — 22,902,888 shares (Direct)

Footnotes (1)

1. F1. On September 30, 2026, Dr. Imhoff converted $115,515.07 outstanding under a September 25, 2025 Convertible Promissory Note, consisting of $110,000 of principal and $5,515.07 of accrued interest, into 1,650,215 shares of common stock at a conversion price of $0.07 per share. The note was convertible at the holder's election upon nonpayment of a scheduled monthly installment of $10,000 plus accrued interest, payable beginning November 30, 2025. By mutual agreement with the Company, the amount converted included $60,000 of deferred installments due April through September 2026 and $50,000 of installments scheduled for October 2026 through February 2027. Following the conversion, the note has been paid in full.

Key Figures

Note balance converted: $115,515.07 Principal converted: $110,000 Accrued interest converted: $5,515.07 +3 more

6 metrics

Note balance converted $115,515.07 Converted on September 30, 2026.

Principal converted $110,000 Component of the balance converted on September 30, 2026.

Accrued interest converted $5,515.07 Component of the balance converted on September 30, 2026.

Common shares acquired 1,650,215 shares Received in the conversion on September 30, 2026.

Conversion price $0.07 per share Price for the September 30, 2026 conversion.

Direct common shares held after conversion 22,902,888 shares Reported following the September 30, 2026 transaction.

Key Terms

Convertible Promissory Note, accrued interest, conversion price, deferred installments

4 terms

Convertible Promissory Note financial

"under a September 25, 2025 Convertible Promissory Note"

A convertible promissory note is a loan a company takes now that can later be turned into shares instead of being repaid in cash. Think of it as lending money with the option to accept ownership in the business down the road; that matters to investors because it affects who gets paid first, how much ownership existing shareholders keep, and the company’s future valuation and cash needs. Terms such as conversion price, interest and maturity determine the financial impact.

accrued interest financial

"and $5,515.07 of accrued interest"

Accrued interest is the amount of interest that has built up on a loan, bond, or similar investment since the last payment date but has not yet been paid. For investors this matters because when you buy or sell a fixed‑income security between payment dates you compensate the other party for that earned interest—think of it like buying a house mid‑month and reimbursing the seller for days of heating already used—so it affects the actual cash you pay, the yield you receive, and short‑term returns.

conversion price financial

"at a conversion price of $0.07 per share"

The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.

deferred installments financial

"$60,000 of deferred installments due April through September 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GTHP shares did John E. Imhoff receive in the conversion?

John E. Imhoff converted the note into 1,650,215 common shares at $0.07 per share on September 30, 2026. His direct common-stock holdings after the conversion were 22,902,888 shares.

What installments were included in John E. Imhoff’s GTHP note conversion?

By mutual agreement with Guided Therapeutics, the converted amount included $60,000 of deferred installments due April through September 2026 and $50,000 scheduled for October 2026 through February 2027. The note allowed conversion at the holder’s election upon nonpayment of a scheduled $10,000 monthly installment plus accrued interest, payable beginning November 30, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/27/2026 - 04:28 PM EDT Accepted by SEC EDGAR 10/27/2026 - 04:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Imhoff John E

(Last) (First) (Middle)

5835 PEACHTREE CORNERS EAST

SUITE B

(Street)

PEACHTREE CORNERS GEORGIA 30092

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GUIDED THERAPEUTICS INC [ GTHP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2026		C(1)		1,650,215	A	$0.07	22,902,888	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Convertible Promissory Note	$0.07	09/30/2026		C(1)			1,650,215(1)	(1)	02/28/2027	Common Stock	1,650,215(1)	(1)	0	D

Explanation of Responses:

1. On September 30, 2026, Dr. Imhoff converted $115,515.07 outstanding under a September 25, 2025 Convertible Promissory Note, consisting of $110,000 of principal and $5,515.07 of accrued interest, into 1,650,215 shares of common stock at a conversion price of $0.07 per share. The note was convertible at the holder's election upon nonpayment of a scheduled monthly installment of $10,000 plus accrued interest, payable beginning November 30, 2025. By mutual agreement with the Company, the amount converted included $60,000 of deferred installments due April through September 2026 and $50,000 of installments scheduled for October 2026 through February 2027. Following the conversion, the note has been paid in full.

	/s/ John E. Imhoff	10/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)